story of the week
Neoadjuvant Nivolumab and Ipilimumab for Resectable Stage III Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
N. Engl. J. Med 2024 Jun 02;[EPub Ahead of Print], CU Blank, MW Lucas, RA Scolyer, BA van de Wiel, AM Menzies, M Lopez-Yurda, LL Hoeijmakers, RPM Saw, JM Lijnsvelt, NG Maher, SM Pulleman, M Gonzalez, A Torres Acosta, WJ van Houdt, SN Lo, AMJ Kuijpers, A Spillane, WMC Klop, TE Pennington, CL Zuur, KF Shannon, BA Seinstra, RV Rawson, JBAG Haanen, S Ch'ng, KAT Naipal, J Stretch, JV van Thienen, MA Rtshiladze, S Wilgenhof, R Kapoor, A Meerveld-Eggink, LG Grijpink-Ongering, ACJ van Akkooi, ILM Reijers, DE Gyorki, DJ Grünhagen, FM Speetjens, SB Vliek, J Placzke, L Spain, RC Stassen, M Amini-Adle, C Lebbé, MB Faries, C Robert, PA Ascierto, R van Rijn, FWPJ van den Berkmortel, D Piersma, A van der Westhuizen, G Vreugdenhil, MJB Aarts, MAM Stevense-den Boer, V Atkinson, M Khattak, MC Andrews, AJM van den Eertwegh, MJ Boers-Sonderen, GAP Hospers, MS Carlino, JB de Groot, E Kapiteijn, KPM Suijkerbuijk, P Rutkowski, S Sandhu, AAM van der Veldt, GV LongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.